Recent Changes in the Clinicopathologic Features of Korean Men with Prostate Cancer: A Comparison with Western Populations

Byun, Seok Soo; Lee, Sangchul; Lee, Eunsik; Seo, Seong Il; Lee, Hyun Moo; Choi, Han Yong; Song, Cheryn; Ahn, Hanjong; Choi, Young Deuk; Cho, Jin Seon

doi:10.3349/ymj.2012.53.3.543

Cited by 29 publications

(39 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another multiinstitutional study from Korea, patients were grouped by the year of surgery, and the median value of PSA was 10.0 ng ml 21 in one group (1995-2003) and 7.5 ng ml 21 in the other group (2004)(2005)(2006)(2007), respectively. 23 Despite a rather high PSA, more contemporary population cohorts presented with lower PSA levels and our results were similar with the latter group. The increased use of the PSA test may have contributed to a trend toward decreasing PSA at diagnosis and this trend is expected to continue.…”

Section: Discussionsupporting

confidence: 86%

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Kim¹,

Lim²,

Shin³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November 2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59-69). The median prostate specific antigen was 7.50 ng ml 21 (IQR: 5.14-11.45) and 39.2% of the patients were classified as intermediate risk and 15.3% were classified as high risk; on final pathological examination, 35.2% of the patients had non-organ confined disease and 37.5% and 14.2% had Gleason scores of 7 and 8-10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were 85.6% and 81.2%, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1% in Gleason scores of 6 or less, 74.5% in a Gleason score of 7, and 58.1% in Gleason scores of 8 or greater, respectively (P,0.001). When stratified by pathologic stage, the BCR-free survival rates were 89.8% in pT2 patients, 66.2% in pT3a patients, and 39.3% in pT3b patients at 5 years following RARP, respectively (P,0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.

show abstract

Section: Discussionsupporting

confidence: 86%

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Kim¹,

Lim²,

Shin³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…The age distribution of a population therefore has a major influence on the absolute numbers of men diagnosed with prostate cancer. Given that life expectancy is expected to increase markedly in many parts of Asia over coming years [27,40,41], the burden of prostate cancer in this region is likely to be a high priority in the future [42]. …”

Section: Increasing Prostate Cancer Incidencementioning

confidence: 99%

Epidemiology of prostate cancer in the Asia-Pacific region

Baade

Youlden

Cramb

et al. 2013

Prostate International

163

136

View full text Add to dashboard Cite

The purpose of this paper was to examine and compare available data on incidence, mortality and survival for countries in the Asia-Pacific region. Incidence data were obtained from GLOBOCAN 2008, other online data sources and individual cancer registries. Country-specific mortality statistics by individual year were sourced from the World Health Organization Statistical Information System Mortality Database. All incidence and mortality rates were directly age-standardised to the Segi World Standard population and joinpoint models were used to assess trends. Data on survival were obtained from country-specific published reports where available. Approximately 14% (122,000) of all prostate cancers diagnosed worldwide in 2008 were within the Asia-Pacific region (10 per 100,000 population), with three out of every four of these prostate cancer cases diagnosed in either Japan (32%), China (28%) or Australia (15%). There were also about 42,000 deaths due to prostate cancer in the Asia-Pacific region (3 per 100,000). For the nine countries with incidence trend data available, eight showed recent significant increases in prostate cancer incidence. In contrast, recent decreases in prostate cancer mortality have been reported for Australia, Japan and New Zealand, but mortality has increased in several other countries. The lack of population-based data across most of the countries in this region limits the ability of researchers to understand and report on the patterns and distribution of this important cancer. Governments and health planners typically require quantitative evidence as a motivation for change. Unless there is a widespread commitment to improve the collection and reporting of data on prostate cancer it is likely that the burden of prostate cancer will continue to increase. Enhancing knowledge transfer between countries where there are differentials in capacity, policy and experience may provide the necessary impetus and opportunity to overcome at least some of the existing barriers.

show abstract

“…Interestingly, the present results are in accordance with previous a Korean study that compared the clinicopathological features of Korean men with PCa with Western populations. 22 Byun et al in their multi-institutional study after analysis of 1582 patients that underwent ORP concluded that Korean men still show relatively worse pathological GS than Western men. 22 Similarly, Man et al reported an incidence of 26.5% GS ≥8 in Asian men compared with 13.8% in non-Asian men (P = 0.003).…”

Section: Discussionmentioning

confidence: 99%

“…22 Byun et al in their multi-institutional study after analysis of 1582 patients that underwent ORP concluded that Korean men still show relatively worse pathological GS than Western men. 22 Similarly, Man et al reported an incidence of 26.5% GS ≥8 in Asian men compared with 13.8% in non-Asian men (P = 0.003). 23 Putting the results of the current study in consideration, and from other Asian series in the literature, it is apparently clear that PCa has shown poor differentiation and a highergrade disease in Asian men compared with their Western peers.…”

Section: Discussionmentioning

confidence: 99%

“…23 Putting the results of the current study in consideration, and from other Asian series in the literature, it is apparently clear that PCa has shown poor differentiation and a highergrade disease in Asian men compared with their Western peers. [20][21][22][23][24][25][26] Table 5 shows analysis of previous Asian cohorts (Korean and non-Korean) in terms of D'Amico risk groups and pathological findings.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stratified analysis of 800 Asian patients after robot‐assisted radical prostatectomy with a median 64 months of follow up

et al. 2016

Self Cite

View full text Add to dashboard Cite

Objective: To report the 5-year oncological outcomes of robot-assisted radical prostatectomy from the largest series ever reported from Asia. Methods: A retrospective analysis of 800 Asian patients who were treated with robotassisted radical prostatectomy from July 2005 to May 2010 in the Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea was carried out. The primary end-point was to evaluate the biochemical recurrence. The secondary end-point was to show the biochemical recurrence-free survival, metastasisfree survival and cancer-specific survival. Results: A total of 197 (24.65%), 218 (27.3%), and 385 (48.1%) patients were classified as low-, intermediate-and high-risk patients according to the D'Amico risk stratification risk criteria, respectively. The median follow-up period was 64 months (interquartile range 28-71 months). The overall incidence of positive surgical margin was 36.6%. There was biochemical recurrence in 183 patients (22.9%), 38 patients (4.8%) developed distant metastasis and 24 patients (3%) died from prostate cancer. Actuarial biochemical recurrence-free survival, metastasis-free survival, and cancer-specific survival rates at 5 years were 76.4%, 94.6% and 96.7%, respectively. Positive lymph node was associated with lower 5-year biochemical recurrence-free survival (9.1%), cancer-specific survival (75.7%) and metastasis-free survival (61.9%) rates (P < 0.001). On multivariable analysis, among all the predictors, positive lymph node was the strongest predictor of biochemical recurrence, cancer-specific survival and metastasis-free survival (P < 0.001). Conclusions: Herein we report the largest robot-assisted radical prostatectomy series from Asia. Robot-assisted radical prostatectomy is confirmed to be an oncologically safe procedure that is able to provide effective 5-year cancer control, even in patients with high-risk disease.

show abstract

Recent Changes in the Clinicopathologic Features of Korean Men with Prostate Cancer: A Comparison with Western Populations

Cited by 29 publications

References 19 publications

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Epidemiology of prostate cancer in the Asia-Pacific region

Stratified analysis of 800 Asian patients after robot‐assisted radical prostatectomy with a median 64 months of follow up

Contact Info

Product

Resources

About